RNase 4 is presented as a biomarker for prostate cancer, inducing AXL activation that promotes AKT/S6K activation and tumor cell proliferation, and its inhibition reduces the growth of xenograft human prostate tumors. The gene discussed is RPS6KB1; the disease is Familial prostate cancer.